Antioxidants and endothelial dysfunction in hyperlipidemia

被引:49
作者
Warnholtz A. [1 ]
Mollnau H. [1 ]
Oelze M. [1 ]
Wendt M. [1 ]
Münzel T. [1 ]
机构
[1] Universitätsklinik Eppendorf, Abteilung für Kardiologie, 20246 Hamburg
关键词
Nitric Oxide; Endothelial Dysfunction; Angiotensin Converting Enzyme; Angiotensin Converting Enzyme Inhibitor; Chronic Smoker;
D O I
10.1007/s11906-001-0081-z
中图分类号
学科分类号
摘要
Endothelial function is abnormal in a variety of diseased states such as hypercholesterolemia and atherosclerosis. This may be secondary to decreased synthesis of nitric oxide (NO) and/or increased degradation of NO due to interaction with superoxide anions. More recent experimental observations demonstrate increased production of superoxide in hyperlipidemia, suggesting that endothelial dysfunction in these states is in part secondary to increased NO metabolism. Enzymes proposed to be involved in increased superoxide production may include xanthine oxidase, the NO synthase, and the NAD(P)H oxidase. Superoxide rapidly reacts with NO to form peroxynitrite (ONOO-), a highly reactive intermediate with cytotoxic properties. Despite experimental evidence for the oxidative stress concept in causing endothelial dysfunction, the results of recent randomized trials to test the influence of antioxidants on coronary event rates and prognosis in patients with coronary artery disease were very disappointing. In all of these studies the use of vitamins such as vitamin E failed to improve the prognosis. In contrast, treatment with angiotensin converting enzyme inhibitors or cholesterollowering drugs improved endothelial dysfunction, prevented the activation of superoxide-producing enzymes in cholesterol-fed animals, reduced coronary event rates, and improved prognosis in patients with coronary artery disease. Therefore, inhibition of superoxide production at the enzymatic level rather than symptomatic superoxide scavenging may be the better choice of treatment. Copyright © 2001 by Current Science Inc.
引用
收藏
页码:53 / 60
页数:7
相关论文
共 62 条
[41]  
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico [see comments], Lancet, 354, pp. 447-455, (1999)
[42]  
N Engl J Med, 342, pp. 154-160, (2000)
[43]  
Thomas S.R., Stocker R., Molecular action of vitamin E in lipoprotein oxidation: Implications for atherosclerosis [in process citation], Free Radic Biol Med, 28, pp. 1795-1805, (2000)
[44]  
Keaney Jr. J.F., Gaziano J.M., Xu A., Et al., Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits, J Clin Invest, 93, pp. 844-851, (1994)
[45]  
Pieper G.M., Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor tetrahydrobiopterin, J Cardiovasc Pharmacol, 29, pp. 8-15, (1997)
[46]  
Cosentino F., Patton S., D'Uscio L.V., Et al., Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats, J Clin Invest, 101, pp. 1530-1537, (1998)
[47]  
Stroes E., Kastelein J., Cosentino F., Et al., Tetrahydrobiopterin restores endothelial function in hypercholesterolemia, J Clin Invest, 99, pp. 41-46, (1997)
[48]  
Heitzer T., Brockhoff C., Mayer B., Et al., Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: Evidence for a dysfunctional nitric oxide synthase, Circ Res, 86, (2000)
[49]  
Beckman J.S., Ye Z.Y., Anderson P.G., Et al., Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry, Biolog Chem Hoppe-Seyler, 375, pp. 81-88, (1994)
[50]  
Petruzzelli S., Puntoni R., Mimotti P., Et al., Plasma 3-nitrotyrosine in cigarette smokers, Am J Respir Crit Care Med, 156, pp. 1902-1907, (1997)